Ping An Healthcare and Technology Company (PANHF) Fair Value & Analysis
Healthcare · US · Market cap $4.3B
Analysis
Ping An Healthcare and Technology Company (PANHF) currently trades at $0.9000, while our model-based Fair Value estimate is $0.5700 — implying the stock looks roughly 36.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Ping An Healthcare and Technology Company Limited, together with its subsidiaries, operates an online healthcare services platform in China. It offers online diagnosis and treatment, online consultation services, audio and video consultations, standardized healthcare service packages, health check-ups, genetic testing, concierge services, health management services, smart device sales, and consulting services. The company also provides online consultation, hospital referral and appointment, inpatient arrangement, and second opinion services; prepaid cards and health check-up services. The company online consultation, hospital referral, inpatient arrangement, second opinion services, electronic prescriptions, health management, prepaid packages for healthcare products and services, provision of products in the Group's health mall, advertising services, and consulting services, as well as operates an insurance agency. In addition it is involved in the integrated finance business. The …
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.